EUCTR2009-011855-40-NL进行中（未招募）不适用
A Phase II Study to Evaluate: Delay in Intravaginal Ejaculatory Latency Time (IELT), Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Randomized, Double Blind, Placebo-Controlled, Parallel Group Study in Men with Premature Ejaculation.
GlaxoSmithKline Research and Development Ltd0 个研究点目标入组 75 人开始时间: 2009年10月7日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1.Males with primary PE, according to the ISSM Consensus Definition (a male sexual dysfunction characterized by ejaculation which always or nearly always occurs prior to or within about one minute of vaginal penetration; and, inability to delay ejaculation on all or nearly all vaginal penetrations; and, negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy)
- •2.Stable heterosexual relationship, with a single non pregnant, nonlactating female partner using adequate contraception (as confirmed by oral questioning of male study subject) in a relationship of greater than >4 months duration. This same partner will be the one with whom the subject makes and records all IELT attempts during the duration of the study.
- •3.Aged between 18 and 50 years (i.e. subjects must not have completed their 50th year birthday at the time of screening).
- •4.The subject must make at least four attempts at sexual intercourse on four separate days during the untreated run in period
- •5.The average intravaginal ejaculatory latency time must be <65 seconds based on the study-provided stop watch assessments
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Positive pre-study Hepatitis B surface antigen or Hepatitis C antibody
- •result and HIV antibody and or confirmatory ELISA test at screening.
- •- History of liver disease, or known hepatic or biliary abnormalities
- •(with the exception of Gilbert's syndrome or asymptomatic gallstones).
- •- Erectile dysfunction (IIEF-EF domain score < 22)
- •- Active/recent (< 6 months) prostatitis (symptoms or treatment seeking for newly diagnosed or flare of symptoms related to previously diagnosed prostatitis).
- •- Any unstable medical, psychiatric or substance abuse disorder.
- •- Penile anatomical abnormalities (e.g. penile fibrosis or Peyronie’s
- •disease) that would significantly impair sexual performance.
- •- Prior implantation of penile implant for erectile dysfunction
- •- Primary hypoactive sexual desire.
- •- Spinal cord injury.
- •- History of seizures, within last 6 months.
- •- History of prostate cancer treated or untreated.
- •- History of prostatectomy or prostate procedures for any cause.
- •- Clinically significant chronic hematological disease which may lead to priapism such as sickle cell anemia, multiple myeloma or leukemia.
- •- Significant active peptic ulceration.
- •- Presence of the following conditions prior to screening: myocardial infarction,
- •coronary bypass surgery, coronary artery angioplasty, unstable angina, clinically
- •evident congestive heart failure, cardiac pacemaker, or cerebrovascular accident.
- •- Cardiac arrhythmia (as defined in protocol)
- •- History of congenital QT prolongation and/or QTc interval >450msec at screening
- •visit (Visit 1) using the Bazett formula.
- •- Mean diastolic/systolic cuff BP > 90/140 mmHg at the screening visit.
- •- History of malignancy within the past five years (other than squamous or basal cell skin cancer).
- •- Any condition which would preclude sexual activity.
- •- Concomitant medications used within 7 days of Visit 1 and or at any time
- •during the study
- •- Subjects who have received any investigational drug (including placebo) within 30
- •days of the screening visit or 5 half lives of the investigational drug whichever is
- •- Abnormal laboratory values:
- •- Serum total testosterone level >25% below the lower limit of normal according to the range of the testing laboratory (obtained in the morning vs in the afternoon).
- •- Subjects with a clinically significant elevation of serum creatinine outside the country specific normal reference ranges.
- •- Clinically significant elevation of AST (of > 126) and/or ALT (of > 144).
- •- Screening PSA value outside the country specific normal reference ranges
- •- TSH outside the country specific normal reference ranges at visit 1.
- •- Free Triiodothyronine [T3] outside the country specific normal reference ranges at visit 1.
- •- Free Thyroxine T4 outside the country specific normal reference ranges at visit 1.
- •- Severe chronic or acute liver disease, history of moderate (Child-Pugh B) or severe
- •(Child-Pugh C) hepatic impairment.
- •- Known hypersensitivity to GSK557296 or any component of the
- •investigational medication.
- •- Subjects who are illiterate or unable to understand the questionnaires or the subject diary.
- •- Subjects who are unwilling or unable to complete the subject diary.
- •- Subjects who are unwilling to be randomized to placebo.
- •- Subject whose sexual partner is actively trying to conceive, and or is unwilling to use a reliable form of birth control as outlined in Section 8.1 for the duration of the trial. Or whose female partner is breast feeding.
- •- Subjects, who in the opinion of the investigator,
研究者
相似试验
进行中（未招募）
不适用
A phase II study to assess the efficacy of intravenous loading doses of Bondronat 6 mg on metastatic bone pain in patients with breast cancer and skeletal metastasesMetastatic bone disease related metastatic bone pain with breast as the primary site.EUCTR2006-001011-29-GRRoche (Hellas) S.A.
尚未招募
2 期
Effect Of Ayurvedic Decoction in skin diseaseCTRI/2023/11/060060Dr Snehal Yashawnt Sarwate
进行中（未招募）
不适用
Ensayo clínico Fase II para evaluar la eficacia y seguridad de la aplicación de Células Progenitoras de Médula Ósea Autóloga expandidas en el tratamiento quirúrgico de pseudoartrosis no hipertróficas de fémur, tibia y húmero, tras un primer fracaso terapéutico.Pseudoartrosis no hipertróficas de fémur, tibia y húmero, tras un primer fracaso terapéuticoMedDRA version: 13Level: LLTClassification code 10017088Term: Fractura no consolidadaEUCTR2010-022909-18-ESHospital General de L?Hospitalet
尚未招募
2 期
effect of Chitrakadi Tail Basti in SciaticaCTRI/2022/02/040271DR SUSHMITA GAJENDRA GOSAVI
进行中（未招募）
不适用
An investigational randomized phase II-(III) study on epirubicin plus cyclophospamide (or CMF) vs nab-paclitaxel plus capecitabine as adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast - ICE IIPrimary breast cancer at non-frail, eldery male and female patientsMedDRA version: 16.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-003995-23-DEGBG Forschungs GmbH